Proprietary Protein Expression PlatformOwning a specialized insect-cell ExpreS2 platform is a durable competitive asset for producing complex antigens and VLP components. This technical moat supports recurring service demand, enables differentiation vs generic CDMOs, and underpins long-term partnership and licensing opportunities.

Low Financial LeverageLow debt provides structural financial flexibility and limits interest burden, giving management more options to fund operations via equity or strategic deals. This reduces insolvency risk and preserves capacity to pursue partnerships or raise capital when needed over the medium term.

Diversified Revenue Channels: Services And PartneringA dual model of contracted platform services plus potential partnering/licensing creates multiple durable revenue pathways. Services can provide steady contract income while partnerships offer milestone/royalty upside, reducing reliance on a single monetization route over 2–6 months and beyond.

Bears Say

Consistent Negative Operating And Free Cash FlowPersistent negative operating and free cash flow indicates the business consumes cash rather than funds itself, creating ongoing funding needs. Continued cash burn increases probability of future equity raises or dilutive financings and constrains strategic investment in platform scaling or pipeline advancement.

Shrinking Equity And Contracting AssetsMaterial declines in equity and assets reflect cumulative losses that erode the balance sheet buffer. A weakened capital base limits borrowing capacity, raises counterparty concerns, and increases the company's sensitivity to further setbacks or larger-than-expected funding needs.

Small, Volatile, Declining Revenue And Persistent LossesVolatile, small, and recently declining revenues with recurring operating losses imply limited internal ability to scale profitability. Without sustainable revenue growth or margin improvement, reliance on external funding and partner deals will persist, constraining long-term operational independence.

5JD0 FAQ

What was ExpreS2ion Biotech Holding AB’s price range in the past 12 months?

ExpreS2ion Biotech Holding AB lowest stock price was €0.54 and its highest was €2.47 in the past 12 months.

What is ExpreS2ion Biotech Holding AB’s market cap?

ExpreS2ion Biotech Holding AB’s market cap is €1.70M.

When is ExpreS2ion Biotech Holding AB’s upcoming earnings report date?

ExpreS2ion Biotech Holding AB’s upcoming earnings report date is May 19, 2026 which is in 70 days.

How were ExpreS2ion Biotech Holding AB’s earnings last quarter?

ExpreS2ion Biotech Holding AB released its earnings results on Feb 19, 2026. The company reported -€0.226 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.226.

Is ExpreS2ion Biotech Holding AB overvalued?

According to Wall Street analysts ExpreS2ion Biotech Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ExpreS2ion Biotech Holding AB pay dividends?

ExpreS2ion Biotech Holding AB does not currently pay dividends.

What is ExpreS2ion Biotech Holding AB’s EPS estimate?

ExpreS2ion Biotech Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ExpreS2ion Biotech Holding AB have?

ExpreS2ion Biotech Holding AB has 3,530,233 shares outstanding.

What happened to ExpreS2ion Biotech Holding AB’s price movement after its last earnings report?

ExpreS2ion Biotech Holding AB reported an EPS of -€0.226 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.853%.

Which hedge fund is a major shareholder of ExpreS2ion Biotech Holding AB?

Currently, no hedge funds are holding shares in DE:5JD0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ExpreS2ion Biotech Holding AB

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.